LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025
LifeVantage reported Q1 fiscal 2025 results with revenue of $47.2 million, down 8.1% year-over-year. Net income per diluted share increased to $0.14 from $0.05 in the prior year. The company launched the MindBody GLP-1 System™ on October 11th. Revenue declined 4.2% in Americas and 19.7% in Asia/Pacific & Europe. Despite lower revenues, adjusted EBITDA improved 11% to $4.4 million. The company maintains its fiscal 2025 guidance of $200-210 million in revenue and adjusted earnings per share of $0.70-$0.80.
LifeVantage ha riportato i risultati del primo trimestre dell'esercizio fiscale 2025, con un fatturato di $47,2 milioni, in calo dell'8,1% rispetto all’anno precedente. L'utile netto per azione diluita è aumentato a $0,14 rispetto a $0,05 dell'anno precedente. L'azienda ha lanciato il MindBody GLP-1 System™ l'11 ottobre. I ricavi sono diminuiti del 4,2% nelle Americhe e del 19,7% in Asia/Pacifico e Europa. Nonostante il calo dei ricavi, l'EBITDA rettificato è migliorato dell'11% a $4,4 milioni. L'azienda conferma le previsioni per l'esercizio fiscale 2025 di $200-210 milioni di fatturato e un utile per azione rettificato di $0,70-$0,80.
LifeVantage informó los resultados del primer trimestre del ejercicio fiscal 2025 con ingresos de $47.2 millones, una disminución del 8.1% en comparación con el año anterior. El ingreso neto por acción diluida aumentó a $0.14 desde $0.05 en el año anterior. La compañía lanzó el MindBody GLP-1 System™ el 11 de octubre. Los ingresos cayeron un 4.2% en las Américas y un 19.7% en Asia/Pacífico y Europa. A pesar de los menores ingresos, el EBITDA ajustado mejoró un 11% a $4.4 millones. La compañía mantiene su guía fiscal 2025 de ingresos de $200-210 millones y ganancias por acción ajustadas de $0.70-$0.80.
라이프반티지(LifeVantage)는 2025 회계연도 1분기 결과를 발표하며 매출이 $47.2 백만으로 지난해 대비 8.1% 감소했다고 보고했습니다. 희석 주당 순이익은 지난해 $0.05에서 $0.14로 증가했습니다. 회사는 10월 11일에 MindBody GLP-1 System™을 출시했습니다. 미국 지역에서는 매출이 4.2%, 아시아/태평양 및 유럽에서는 19.7% 감소했습니다. 매출 감소에도 불구하고 조정 EBITDA는 11% 개선되어 $4.4 백만에 달했습니다. 회사는 2025 회계연도에 매출 목표를 $200-210 백만으로, 조정 주당 순이익을 $0.70-$0.80으로 유지할 것이라고 밝혔습니다.
LifeVantage a annoncé les résultats du premier trimestre de l'exercice fiscal 2025 avec des revenus de $47,2 millions, en baisse de 8,1% par rapport à l'année précédente. Le bénéfice net par action diluée a augmenté à $0,14 contre $0,05 l'an dernier. La société a lancé le MindBody GLP-1 System™ le 11 octobre. Les revenus ont diminué de 4,2% en Amérique et de 19,7% en Asie/Pacifique et en Europe. Malgré des revenus en baisse, l'EBITDA ajusté a progressé de 11% pour atteindre $4,4 millions. La société maintient ses prévisions pour l'exercice fiscal 2025, avec des revenus estimés entre $200 et $210 millions et un bénéfice par action ajusté de $0,70 à $0,80.
LifeVantage berichtete über die Ergebnisse des ersten Quartals des Geschäftsjahres 2025 mit einem Umsatz von $47,2 Millionen, was einem Rückgang von 8,1% im Vergleich zum Vorjahr entspricht. Der Nettogewinn pro verwässerter Aktie stieg von $0,05 im Vorjahr auf $0,14. Das Unternehmen hat am 11. Oktober das MindBody GLP-1 System™ eingeführt. Der Umsatz ging in den Amerikas um 4,2% und in Asien/Pazifik & Europa um 19,7% zurück. Trotz rückläufiger Umsätze verbesserte sich das bereinigte EBITDA um 11% auf $4,4 Millionen. Das Unternehmen hält an seiner Umsatzprognose von $200-210 Millionen und einem bereinigten Gewinn pro Aktie von $0,70-$0,80 für das Geschäftsjahr 2025 fest.
- Net income per diluted share increased to $0.14 from $0.05 year-over-year
- Adjusted EBITDA improved 11% to $4.4 million
- Gross profit margin remained strong at 79.9%
- Commissions and incentives expense decreased to 43.0% from 43.8% of revenue
- Operating income increased to $2.6 million from $0.7 million
- Revenue decreased 8.1% to $47.2 million
- Americas revenue declined 4.2%
- Asia/Pacific & Europe revenue fell 19.7%
- Cash from operations showed negative $0.6 million compared to positive $4.8 million last year
- Cash and cash equivalents decreased to $14.6 million from $16.9 million in June 2024
Insights
The Q1 FY2025 results present a mixed picture for LifeVantage. While revenue declined by
Key positives include improved operational efficiency with SG&A expenses dropping to
However, concerning trends include declining revenues across all regions, with Asia/Pacific & Europe showing significant weakness (-
The weight management market entry through the MindBody GLP-1 System™ is strategically significant, aligning with the booming GLP-1 trend. This positions LifeVantage to capitalize on the rapidly expanding weight management sector, which has seen increased consumer interest following the success of drugs like Wegovy and Ozempic.
The company's direct selling model faces challenges, evidenced by declining revenues in all regions. The
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2024.
First Quarter Fiscal 2025 Summary*:
- Revenue of
$47.2 million , a decrease of8.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, first quarter revenue was down approximately7.7% ; - Revenue in the Americas decreased
4.2% , and revenue in Asia/Pacific & Europe decreased19.7% . Excluding the negative impact of foreign currency fluctuations, first quarter revenue in Asia/Pacific & Europe decreased approximately18.7% ; - Net income per diluted share was
$0.14 , versus$0.05 per diluted share a year ago; - Adjusted earnings per diluted share was
$0.15 , compared to$0.13 a year ago; and - Adjusted EBITDA was
$4.4 million compared to$4.0 million a year ago.
* All comparisons are on a year over year basis and compare the first quarter of fiscal 2025 to the first quarter of fiscal 2024, unless otherwise noted.
“It’s an incredible time to be at LifeVantage as we just launched the MindBody GLP-1 System™, an amazing innovation targeting consumers searching for an effective, sustainable weight management solution. This product, launched on October 11th, significantly expands our total addressable market and the initial response from our independent Consultants and customers has been overwhelming,” said Steve Fife, President and CEO of LifeVantage. “In the first quarter, we again delivered solid profitability metrics despite lower revenues, including an increase of
First Quarter Fiscal 2025 Results
For the first quarter ended September 30, 2024, the Company reported revenue of
Gross profit for the first quarter of fiscal 2025 was
Commissions and incentives expense for the first quarter of fiscal 2025 was
Selling, general and administrative (SG&A) expense for the first quarter of fiscal 2025 was
Operating income for the first quarter of fiscal 2025 was
Net income for the first quarter of fiscal 2025 was
Adjusted EBITDA was
Balance Sheet & Liquidity
The Company used
Share Repurchase
During the first quarter, the Company repurchased 0.1 million shares of its common stock for an aggregate purchase price of
Dividend Announcement
Today the Company announced the declaration of a cash dividend of
Fiscal Year 2024 Guidance
The Company continues to expect revenue in the range of
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, November 12, 2024, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13749350, or (412) 317-6671 from international locations, and entering confirmation code 13749350.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations or directly at https://viavid.webcasts.com/starthere.jsp?ei=1691932&tp_key=975c2e4123. The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation® (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs to optimize cellular function—just as nature intended. LifeVantage owns the identification, research, development, formulation, and sale of advanced nutrigenomic activators. The line of scientifically validated dietary supplements includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System™, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own sales business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Cautionary Note Regarding Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, the impact of COVID-19 on our business, expected financial performance, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.
Investor Relations Contacts:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||
CONSOLIDATED BALANCE SHEETS | |||||||
(Unaudited) | |||||||
(In thousands, except per share data) | September 30, 2024 | June 30, 2024 | |||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 14,596 | $ | 16,886 | |||
Accounts receivable | 2,968 | 2,949 | |||||
Income tax receivable | 886 | 313 | |||||
Inventory, net | 16,914 | 15,055 | |||||
Prepaid expenses and other | 3,451 | 2,443 | |||||
Total current assets | 38,815 | 37,646 | |||||
Property and equipment, net | 7,477 | 7,813 | |||||
Right-of-use assets | 9,409 | 9,569 | |||||
Intangible assets, net | 290 | 323 | |||||
Deferred income tax asset | 4,784 | 4,268 | |||||
Other long-term assets | 685 | 680 | |||||
TOTAL ASSETS | $ | 61,460 | $ | 60,299 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities | |||||||
Accounts payable | $ | 5,270 | $ | 5,853 | |||
Commissions payable | 6,530 | 6,569 | |||||
Income tax payable | 47 | 202 | |||||
Lease liabilities | 1,897 | 1,811 | |||||
Other accrued expenses | 8,328 | 7,874 | |||||
Total current liabilities | 22,072 | 22,309 | |||||
Long-term lease liabilities | 11,466 | 11,801 | |||||
Other long-term liabilities | 225 | 198 | |||||
Total liabilities | 33,763 | 34,308 | |||||
Commitments and contingencies | |||||||
Stockholders' equity | |||||||
Preferred stock — par value | — | — | |||||
Common stock — par value | 1 | 1 | |||||
Additional paid-in capital | 137,347 | 136,644 | |||||
Accumulated deficit | (108,526 | ) | (108,738 | ) | |||
Accumulated other comprehensive loss | (1,125 | ) | (1,916 | ) | |||
Total stockholders’ equity | 27,697 | 25,991 | |||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 61,460 | $ | 60,299 |
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
(Unaudited) | |||||||
Three Months Ended September 30, | |||||||
(In thousands, except per share data) | 2024 | 2023 | |||||
Revenue, net | $ | 47,214 | $ | 51,364 | |||
Cost of sales | 9,491 | 10,180 | |||||
Gross profit | 37,723 | 41,184 | |||||
Operating expenses: | |||||||
Commissions and incentives | 20,305 | 22,473 | |||||
Selling, general and administrative | 14,848 | 17,962 | |||||
Total operating expenses | 35,153 | 40,435 | |||||
Operating income | 2,570 | 749 | |||||
Other income (expense): | |||||||
Interest income, net | 59 | 168 | |||||
Other expense, net | (51 | ) | (88 | ) | |||
Total other income | 8 | 80 | |||||
Income before income taxes | 2,578 | 829 | |||||
Income tax expense | (752 | ) | (200 | ) | |||
Net income | $ | 1,826 | $ | 629 | |||
Net income per share: | |||||||
Basic | $ | 0.15 | $ | 0.05 | |||
Diluted | $ | 0.14 | $ | 0.05 | |||
Weighted-average shares outstanding: | |||||||
Basic | 12,162 | 12,537 | |||||
Diluted | 12,824 | 13,109 |
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||||||||||
Revenue by Region | |||||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||
(In thousands) | 2024 | 2023 | |||||||||||||||||||||
Americas | $ | 36,892 | 78 | % | $ | 38,514 | 75 | % | |||||||||||||||
Asia/Pacific & Europe | 10,322 | 22 | % | 12,850 | 25 | % | |||||||||||||||||
Total | $ | 47,214 | 100 | % | $ | 51,364 | 100 | % | |||||||||||||||
Active Accounts | |||||||||||||||||||||||
(Unaudited) | |||||||||||||||||||||||
As of September 30, | |||||||||||||||||||||||
2024 | 2023 | Change from Prior Year | Percent Change | ||||||||||||||||||||
Active Independent Consultants(1) | |||||||||||||||||||||||
Americas | 31,000 | 66 | % | 32,000 | 62 | % | (1,000 | ) | (3.1 | )% | |||||||||||||
Asia/Pacific & Europe | 16,000 | 34 | % | 20,000 | 38 | % | (4,000 | ) | (20 | )% | |||||||||||||
Total Active Independent Consultants | 47,000 | 100 | % | 52,000 | 100 | % | (5,000 | ) | (9.6 | )% | |||||||||||||
Active Customers(2) | |||||||||||||||||||||||
Americas | 61,000 | 80 | % | 66,000 | 78 | % | (5,000 | ) | (7.6 | )% | |||||||||||||
Asia/Pacific & Europe | 15,000 | 20 | % | 19,000 | 22 | % | (4,000 | ) | (21.1 | )% | |||||||||||||
Total Active Customers | 76,000 | 100 | % | 85,000 | 100 | % | (9,000 | ) | (10.6 | )% | |||||||||||||
Active Accounts(3) | |||||||||||||||||||||||
Americas | 92,000 | 75 | % | 98,000 | 72 | % | (6,000 | ) | (6.1 | )% | |||||||||||||
Asia/Pacific & Europe | 31,000 | 25 | % | 39,000 | 28 | % | (8,000 | ) | (20.5 | )% | |||||||||||||
Total Active Accounts | 123,000 | 100 | % | 137,000 | 100 | % | (14,000 | ) | (10.2 | )% | |||||||||||||
(1) Active Independent Consultants have purchased product in the prior three months for retail or personal consumption. | |||||||||||||||||||||||
(2) Active Customers have purchased product in the prior three months for personal consumption only. | |||||||||||||||||||||||
(3) Total Active Accounts is the sum of Active Independent Consultant accounts and Active Customer accounts. |
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA | |||||||
(Unaudited) | |||||||
Three Months Ended September 30, | |||||||
(In thousands) | 2024 | 2023 | |||||
GAAP Net income | $ | 1,826 | $ | 629 | |||
Interest income, net | (59 | ) | (168 | ) | |||
Provision for income taxes | 752 | 200 | |||||
Depreciation and amortization | 797 | 918 | |||||
Non-GAAP EBITDA: | 3,316 | 1,579 | |||||
Adjustments: | |||||||
Stock compensation expense | 917 | 978 | |||||
Other expense, net | 51 | 88 | |||||
Other adjustments(1) | 144 | 1,345 | |||||
Total adjustments | 1,112 | 2,411 | |||||
Non-GAAP Adjusted EBITDA | $ | 4,428 | $ | 3,990 | |||
(1) Other adjustments breakout: | |||||||
Nonrecurring proxy contest related expenses | $ | — | $ | 1,245 | |||
Key management severance expenses | 38 | 100 | |||||
Executive team recruiting and transition expenses | 106 | — | |||||
Total adjustments | $ | 144 | $ | 1,345 |
LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS | |||||||
(Unaudited) | |||||||
Three Months Ended September 30, | |||||||
(In thousands) | 2024 | 2023 | |||||
GAAP Net income | $ | 1,826 | $ | 629 | |||
Adjustments: | |||||||
Nonrecurring proxy contest related expenses | — | 1,245 | |||||
Key management severance expenses | 38 | 100 | |||||
Executive team recruiting and transition expenses | 106 | — | |||||
Tax impact of adjustments(1) | (37 | ) | (303 | ) | |||
Total adjustments, net of tax | 107 | 1,042 | |||||
Non-GAAP Net income: | $ | 1,933 | $ | 1,671 | |||
Three Months Ended September 30, | |||||||
2024 | 2023 | ||||||
Diluted earnings per share, as reported | $ | 0.14 | $ | 0.05 | |||
Total adjustments, net of tax | 0.01 | 0.08 | |||||
Non-GAAP adjusted diluted earnings per share(2) | $ | 0.15 | $ | 0.13 | |||
(1) Tax impact is based on the estimated annual tax rate for the years ended June 30, 2024 and 2023, respectively. | |||||||
(2) May not add due to rounding. |
FAQ
What was LifeVantage's (LFVN) revenue in Q1 2025?
What is LifeVantage's (LFVN) earnings guidance for fiscal 2025?
When did LifeVantage (LFVN) launch the MindBody GLP-1 System?